enGene Inc.

ENGN | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.96

+$0.05 (+2.62%)

At close: Sep 21, 2026, 4:00 PM ET

$1.96

$0 (0.00%)

Pre-market: Sep 22, 2026, 4:00 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+2.62%

(1D)

Rating

Updated: Sep 2, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $131.3M

1D Range

1.92 1.97

52W Range

1.40 12.25

Valuation (TTM)

PE -7

PB 0.57

EV/EBITDA 0.96

Valuation (NTM)

Forward PE N/A

Forward PEG 0.35

Price Target $3

Cash Flow

FCF Yield -79.2%

SBC Adj. FCF Yield -92.4%

SBC Impact -16.7%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 88.3% | -21.2%

FCF 3Y | 5Y -43.1% | -48.0%

Returns

ROA -1.7%

ROE -2.1%

ROIC -1.6%

Financial Health

Net Cash

$258.4M

Current Ratio 10.21

Interest Coverage -1.53

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by adminis...

Sector Healthcare

Industry Biotechnology

Employees 82

IPO Date Jan 31, 2022

Website www.engene.com

Fiscal Year November - October

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Hold

Price Target

Upside

+53.06%

Buy (2)

Hold (4)

Sell (1)

Analyst Details ➞